Moving Forward: Respirology Supplement on Chronic Airway Inflammation Research in China.
Zhi-Hua Chen,Hua-Hao Shen
DOI: https://doi.org/10.1111/resp.12202
2013-01-01
Abstract:It gives us great pleasure to introduce this Respirology supplement on chronic airway inflammation research, with an emphasis on asthma and chronic obstructive pulmonary disease (COPD). The publication of this issue would not have been possible without the contributions of many people. WileyBlackwell helped to launch the project and sent out a call for papers from China. A Chinese editorial board comprised of Professors Rongchang Chen, Jian Kang, Xin Zhou, Chuntao Liu and Guangfa Wang provided the first-tier peer review process, and we are immensely grateful for their support. Lily Jiang, the production editor, has offered excellent support with managing the review process and preparing the issue for publication, and we are most grateful to her. We originally received 22 submissions from Chinese respirologists; after a thorough peer-review process, seven of these, including two reviews, were accepted for publication. The accepted original papers cover both basic and clinical research into asthma and COPD, with one review each dedicated to COPD and asthma, respectively. In the first original research paper, Liang et al. show that p38MAPK is critically involved in asthma triggered by a combination of ozone and ovalbumin, and that co-treatment of dexamethasone and p38MAPK inhibitor effectively reduced lung inflammation and inhibited airway remodelling. This suggests that p38MAPK is likely to be involved in corticosteroid insensitivity of severe asthma. The second research paper demonstrates a critical role for peroxisome proliferator-activated receptor-gamma in the airway’s inflammatory response to cigarette smoke exposure in human bronchial epithelial 16-HBE cells. The third study examines the mechanisms behind respiratory syncytial virus-induced wheezing, and demonstrates that the virus infection induces mRNA expression of Leukotriene C4 synthase and increases protein levels of cysteinyl leukotrienes in 16-HBE cells. In the following two clinical investigations, the first examines the effects of nebulized high-dose budesonide on moderate-to-severe acute exacerbation of asthma in children, while the second explores the efficacy and safety of procaterol in combination with inhaled budesonide for treatment of cough-variant asthma. The first review by Zhou and Chen summarizes the risk factors and interventions for COPD in China. The second review summarizes the major achievements of asthma research in China between 2008 and 2012. Asthma and COPD are both obstructive airway diseases that involve chronic inflammation of the respiratory tract. These two chronic airway disorders are both very common and have a significant impact on individuals, their families and society. Asthma affects 300 million individuals worldwide, with the prevalence ranging from 1% to 18% of the population in different countries. COPD is a leading cause of morbidity and mortality worldwide, and is estimated to be the fourth leading cause of death by 2020. In China, COPD was the third leading cause of death in 2010. Fortunately, more and more people acknowledge the seriousness of asthma and COPD, and importantly, more and more clinicians and scientists are devoting themselves to research into asthma and COPD. These efforts are significantly increasing our understanding of the disease prevalence, risk factors, control status, pathogenesis and new prevention or treatment strategies. The number of asthma and COPD research publications from China has increased substantially over the last decade. Searching Pubmed for the key words ‘asthma, China’ or ‘COPD, China’, retrieved 2672 or 1234 results respectively (to date of September 6, 2013). A total of 52 asthma papers and 22 COPD papers were published from China in 2000, which has increased to 336 asthma and 194 COPD papers in 2012 (Fig. 1). It is not surprising that the number of COPD publications is lower than the number of asthma publications, as COPD research has progressed less worldwide than asthma research due to the disease complexity and challenges associated with developing appropriate animal models. In 2000, the total numbers of asthma and COPD publications from China made up only a very small part of those worldwide, with 1.9% and 3.0% for asthma and COPD, respectively. However, it is encouraging to see that both of these ratios increased in 2012 to approximately 5.6%. Based on the upward trend observed in the last decade, we expect original respiratory research from China to continue to increase its international profile in the coming years. From all the studies on chronic airway diseases in China, we would like to highlight the following studies of great significance. In a 2-year follow-up study in young students, Zhong et al. found that a small population (around 2.5%) had asymptomatic airway hyperresponsiveness, and in this group, 39.5% finally developed symptomatic asthma. This study introduced the concept of ‘potential asthma’, which has now been widely accepted. We recently identified another new phenotype of asthma, chest tightness variant asthma, whose sole presenting manifestation is chest tightness. These new concepts will lead bs_bs_banner